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Abstract: Background: Transient receptor potential (TRP) channels control multiple processes involved
in cancer progression by modulating cell proliferation, survival, invasion and intravasation, as well as,
endothelial cell (EC) biology and tumor angiogenesis. Nonetheless, a complete TRP expression
signature in tumor vessels, including in prostate cancer (PCa), is still lacking. Methods: In the present
study, we profiled by qPCR the expression of all TRP channels in human prostate tumor-derived
ECs (TECs) in comparison with TECs from breast and renal tumors. We further functionally
characterized the role of the ‘prostate-associated’ channels in proliferation, sprout formation and
elongation, directed motility guiding, as well as in vitro and in vivo morphogenesis and angiogenesis.
Results: We identified three ‘prostate-associated’ genes whose expression is upregulated in prostate
TECs: TRPV2 as a positive modulator of TEC proliferation, TRPC3 as an endothelial PCa cell attraction
factor and TRPA1 as a critical TEC angiogenic factor in vitro and in vivo. Conclusions: We provide
here the full TRP signature of PCa vascularization among which three play a profound effect on EC
biology. These results contribute to explain the aggressive phenotype previously observed in PTEC
and provide new putative therapeutic targets.
Keywords: tumor angiogenesis; calcium channel; migration; TRP; prostate cancer
1. Introduction
Transient receptor potential (TRP) channels form a 28-member superfamily of nonselective
channels mostly permeable to both monovalent and divalent cations, which is subgrouped into six
main families, namely, TRPC (canonical), TRPV (vanilloid), TRPM (melastatin), TRPP (polycystin),
TRPML (mucolipin), and TRPA (ankyrin). Despite their structural similarities, TRP channels are
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polymodal molecular sensors and are activated by a range of external stimuli (including temperature,
light, sound, chemicals, and touch) and changes in local microenvironment [1]. These observations
suggest that the physiologically relevant stimulus for any given TRP is governed by the specific cellular
context, which dramatically changes during carcinogenesis [2].
Indeed, TRP-activated signaling pathways have profound effects on a variety of physiological
and pathological processes, including cancer [3,4]. Accumulating evidence demonstrates that the
development of some cancers involves ion channels, thereby classifying these diseases as a special
type of ‘channelopathy’, called ‘oncochannelopathy’ [2,4,5]. Several studies have demonstrated that TRP
channels control multiple aspects of cancer progression at all stages and modulate Ca2+-regulated
pathways such as cell proliferation and survival, migration and angiogenesis [2,6]. It is therefore not
surprising that the expression of some TRP channels is altered during tumor growth and metastasis,
and consequently a TRP expression signature could characterize the phenotype of a tumor, including
prostate cancer (PCa) [7]. Several studies have identified and proposed TRP channels as new prognostic
and therapeutic targets for PCa [8–12]. In particular, we proposed that at least five TRP members
(namely, TRPM8, TRPV6, TRPC6, TRPV2 and TRPA1) could be of particular interest in PCa therapy
since their expression and function define and modulate specific stages of PCa progression (for a
review see [5]).
Nevertheless, little is known about the role of TRP channels in PCa angiogenesis, even though
the crucial role of vascularization in tumor growth, invasion into surrounding tissues and metastasis
is well studied. Indeed, as for other cancers, tumor angiogenesis is a well-recognized hallmark of
aggressive PCa progression [13]. Immunohistochemical staining on normal and tumor tissues from
the prostate showed that the endothelial cell (EC) population is enriched in PCa tissues compared to
that in normal tissues, whereas the EC population decreases upon castration and gradually recovers
with time [14]. A growing number of studies implicate TRP channels in EC biology, as well as in tumor
angiogenesis. Several members of the TRP superfamily (i.e., TRPC1, TRPC4, TRPC6, TRPM7, TRPV1,
TRPV4 and TRPM8) appear to be heterogeneously expressed in different EC types and have a key role
during multiple functions in ECs, including cell proliferation, survival, motility and tubulogenesis
in vitro [15–17]. However, until now, most available data focus on the function of a single channel
rather a global view of the regulation of all TRP channels in PCa development and angiogenesis [16].
The definition of a specific expression pattern is of particular interest, as it is now evident that
specific stages of cancer progression, such as angiogenesis, are not caused by mutations in the trp
genes but rather by altered expression of the wild-type protein [4]. Indeed, the aim of this study is to
profile the expression of TRP channels during PCa angiogenesis and to identify the specific molecular
modulators of this process, thereby identifying novel therapeutic targets. We have therefore analyzed
the complete expression profile of all trp channels in prostate tumor-derived ECs (TEC). To verify the
PCa specificity of the molecular candidates identified, we also profiled trp expression signatures in ECs
derived from breast and renal tumors. We identified four ‘prostate-associated’ genes whose expression is
significantly and specifically deregulated in prostate TECs relative to normal ECs. Most importantly,
we functionally characterized the role of the ‘prostate-associated’ trp channels (i.e., trpa1, trpv2, and trpc3)
upregulated in TECs in the modulation of key biological processes occurring during angiogenesis, such
as EC proliferation, motility, regulation of tubulogenesis in vitro and angiogenic sprouting in vivo.
2. Results
2.1. Identification of the trp Expression Signature Associated with PTEC
To define a complete ‘TRP signature’ for the PCa endothelium, we performed gene expression
profiling of TRP channels by means of real-time qPCR in TECs from the prostate and compared the
profiles to those of breast and renal tumors. For this purpose, we designed primers targeting the
functional region for all members of the TRP channel superfamily (ankyrin 1, trpa1; canonical 1-7, trpc1-7;
melastatin 1-8, trpm1-8; vanilloid 1-6, trpv1-6; polycystin 2-3, trpp2-3; and mucolipin 1-3, trpm1-3).
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We screened three primary human TEC primary cell lines derived from the prostate (PTEC1-3,
corresponding to three different patients), which were previously characterized in our laboratory [18].
We also screened TECs from breast and renal tumors (designated BTEC and RTEC, respectively) [19,20].
Expression profiles of TECs were compared to those of several normal human ECs, namely, human
umbilical vein ECs (HUVECs), human microvascular ECs from derma (HMECs), glomerular ECs from
the kidney (GECs), and the commercially available human prostatic microvascular ECs (HPrMEC,
ScienCell Research Laboratories, Carlsbad, CA, USA).
Differential analysis by the ∆∆CT method and fold change analysis of the expression values
resulting from the qPCR screening were used to select ‘prostate-associated’ genes that are deregulated
during PCa angiogenesis (Figure 1c).
The ∆∆CT method was applied to calculate the relative trp expression level in both normal ECs
and TECs. ∆∆CT values in TECs were normalized to different normal ECs: PTEC1-3, BTEC and RTEC
expression profiles were compared to those of HPrMEC, HMEC and GEC respectively (Figure 1a).
As shown in the heatmap (Figure 1a), the complete profiling of trp channel expression revealed
several genes that are deregulated between normal ECs and TECs. Notably, compared to those in
HPrMEC six genes are significantly deregulated in PTEC1-3 (Figure 1b), and among these, trpa1 is the
only upregulated gene (Figure 1d, Figure S1c). To identify a specific profile for PCa vascularization,
we compared the expression profiles of TECs from PCa to those of TECs from breast and renal cancers.
Four mRNA (i.e., trpc1, trpc4, trpm1, and trpml1) are downregulated in all TECs compared to that
in normal ECs; moreover, trpm7 is downregulated in PTEC and RTEC but upregulated in BTEC
(Figure 1a, Figure S1c). Based on differential statistical analysis, trpa1 is the only ‘prostate-associated’
gene (Figure 1c). In fact, in RTEC, trpa1 expression is barely detectable, and trpa1 is downregulated
relative to that in renal GECs; in BTEC, trpa1 is expressed at low levels, being downregulated relative
to that in HPrMEC and upregulated relative to that in other normal ECs (HUVEC, HMEC and GEC)
(Figure 1d). We further analyzed the expression profiles in PTEC, in comparison with HPrMEC
(Figure 1e). Notably, twelve genes display at least 2-fold change in their expression relative to those in
HPrMEC in at least two patient-derived PTEC (Figure 1e, blue and red dots, Figure 1c). Among these
genes, trpa1, trpv2, and trpc3 are specifically upregulated in PTEC but not in the other TECs (Figure 1d).
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differentially deregulated (panels a,b), and twelve genes displayed at least 2-fold change in their 
expression in at least two patient lines (panel e). Among these, four channels (trpa1, trpv2, trpc3 and 
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HPrMEC. Blue dots indicate genes with more than 2-fold change in at least one PTEC line relative to 
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trpc6), with more than 2-fold change in at least 2 PTEC lines out of three. Correlation values for trp 
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trpc6) were selected as ‘prostate-associated’. (d) Real-time qPCR analysis of mRNA expression shows
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In particular, trpa1, already identified by differential analysis (Figure 1b,c), is strongly upregulated
in PTEC1-3 relative to that in HPrMEC (51.72-fold increase) (Figure 1d, Figure S1d), as well as relative
to that in HUVEC and HMEC (where channel expression is barely detectable) and GEC. trpv2 is
upregulated by greater than 2-fold (2.47-fold increase) in PTEC1 and PTEC3 (PTEC1,3) relative to that
in HPrMEC (Figure 1d, Figure S1d) and is overall markedly upregulated compared to that in other
normal ECs while; however, in other TECs (RTEC and BTEC) and i normal HMEC, trpv2 expression
is barely det ctable (Figure 1d). trpc3 is strongly upregula ed in PTEC1,3 (39.38-fold increase) relative
to that in no mal HPrMEC (Figure 1d, Figure S1d), and this up-regulation is also consistent relative to
that i HUVEC and HMEC (Figure 1d). trpc3 is downregulated in RTEC relative that in the normal
GEC, while in BTEC trpc3 is downregulated relative to that in HMEC but upregulated relative to
that in HUVEC and HPrMEC (Figure 1d). The only trp gene showing a specific do nregulation in
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PTEC is trpc6, being 34-fold downregulated compared to that in HPrMEC (Figure 1d, Figure S1d).
No significant change in trpc6 expression is observed between RTEC and GECs, while BTEC display
upregulation of trpc6 relative to that in all normal ECs (HUVEC, HMEC, andGEC) but not to HPrMEC
(Figure 1d).
These data therefore highlight four channels, namely, trpa1, trpv2, trpc3 and trpc6, as ‘prostate-associated’
(Figure 1c), displaying at least 2-fold change in expression compared to that in normal ECs (Figure 1e,
red dots); additionally, these genes show differential regulation in PTEC compared with those in other
TECs (Figure 1d).
2.2. TRPA1, TRPV2, TRPC3 and TRPC6 Expression in PCa Patients
Given that we identified trpa1, trpv2, trpc3 and trpc6 as ‘prostate-associated’ genes that are deregulated
in PTEC compared to that in normal HPrMEC, we further studied their expression at the protein level
in vivo by immunohistochemistry on PCa tissues (Figure 2a,b) from ten patients (see materials and
methods section) and in vitro by western blotting on proteins extracted from PTEC1-3 (Figure S2).
Immunohistochemical analysis highlighted TRPA1 expression in human PCa tissues, showing positive
TRPA1 staining in intratumoral ECs (Figure 2aaii). In particular, endothelial expression of TRPA1 was
observed in tumor areas in all patient tissues (n = 10/10), with negative staining on cancer cells in 8
out of 10 patient samples (Figure 2aaii). In the normal areas of the tissues, we observed focal positive
staining in epithelial cells with diffuse staining in ECs in all patients (Figure 2aai). We quantified TRPA1
expression by western blotting in PTEC and compared it to the expression in HPrMEC confirming
TRPA1 upregulation in all PTEC with a mean increase by 1.78-fold (Figure S2a).
Immunohistochemical analysis in PCa patient samples confirmed TRPV2 overexpression in
intratumoral ECs, showing positive expression in seven of 10 patient samples (Figure 2abii), with
variable expression in tumor cells (Figure 2abii). However, TRPV2 expression was not detected in ECs
in histologically normal areas (n = 0/10) (Figure 2abi). The expression pattern at the protein level was
confirmed by western blotting, showing TRPV2 overexpression in PTECs compared to that in HPrMEC
(Figure S2b), in accordance with the mRNA levels in the different PTEC (Figure S1d).
Immunohistochemistry did not confirm TRPC3 expression patterns in PTEC mRNA profiling,
revealing negative TRPC3 staining in ECs in all normal areas (n = 10/10 patients) (Figure 2aci), but only
one tumor area (n = 1/10) showed faint positive TRPC3 staining in ECs (Figure 2acii). Nevertheless,
trpc3 already shows a certain degree of variability since it is overexpressed in two PTEC (PTEC1,3) out
of three. The overexpression pattern detected by mRNA profiling was confirmed by western blotting,
showing an upregulation in all PTECs (Figure S2c).
Cancers 2019, 11, x 5 of 29 
 
downregulation in PTEC is trpc6, being 34-fold downregulated compared to that in HPrMEC (Figure 
1d, Figure S1d). No significant change in trpc6 expression is observed between RTEC and GECs, while 
BTEC display upregulation of trpc6 relative to that in all normal ECs (HUVEC, HMEC, andGEC) but 
not to HPrMEC (Figure 1d). 
These data therefore highlight four channels, namely, trpa1, trpv2, trpc3 and trpc6, as ‘prostate-
associated’ (Figure 1c), displaying at least 2-fold change in expression compared to that in normal ECs 
(Figure 1e, red dots); additionally, these genes show differential regulation in PTEC compared with 
those in other TECs (Figure 1d). 
2.2. TRPA1, TRPV2, TRPC3 and TRPC6 Expression in PCa Patients 
Given that we identified trpa1, trpv2, trpc3 and trpc6 as ‘prostate-associated’ genes that are 
deregulated in PTEC compared to that in normal HPrMEC, we further studied their expression at the 
protein level in vivo by immunohistochemistry on PCa tissues (Figure 2a,b) from ten patients (see 
materials and methods section) and in vitro by western blotting on proteins extracted from PTEC1-3 
(Figure S2). Immunohistochemical analysis highlighted TRPA1 expression in human PCa tissues, 
showing positive TRPA1 staining in intratumoral ECs (Figure 2aaii). In particular, endothelial 
expr ssion of TRPA1 was observ d in tumor areas in all patie t tissu s (n = 10/10), with negative 
staining on cancer ce ls in 8 out of 10 patient samples (Figure 2aaii). In th  normal areas of the tissues, 
we observed focal po itive staining in epithelial cells with diffuse staining in ECs in all patients 
(Figure 2aai). We quantified TRPA1 expression by western blotting in PTEC a d compared it to the 
expression in HPrMEC confirming TRPA1 upregulation in all PTEC with a mean increase by 1.78-
fold (Figure S2a). 
Immunohistochemical analysis in PCa patient samples confirmed TRPV2 overexpression in 
intratumoral ECs, showing positive expression in seven of 10 patient samples (Figure 2abii), with 
variable expression in tumor cells (Figure 2abii). However, TRPV2 expression was not detected in ECs 
in histologically normal areas (n = 0/10) (Figure 2abi). The expression pattern at the protein level was 
confirmed by western blotting, showing TRPV2 overexpression in PTECs compared to that in 
HPrMEC (Figure S2b), in accordance with the mRNA levels in the different PTEC (Figure S1d). 
Immunohistochemistry did not confirm TRPC3 expression patterns in PTEC mRNA profiling, 
revealing negative TRPC3 staining in ECs in all normal areas (n = 10/10 patients) (Figure 2aci), but 
only one tumor area (n = 1/10) showed faint positive TRPC3 staining in ECs (Figure 2acii). 
Nevertheless, trpc3 already shows a certain degree of variability since it is overexpressed in two PTEC 
(PTEC1,3) out of three. The overexpression pattern detected by mRNA profiling was confirmed by 
western blotting, showing an upregulation in all PTECs (Figure S2c). 
 
Figure 2. Cont. Figure 2. Cont.
Cancers 2019, 11, 956 6 of 29
Cancers 2019, 11, x 6 of 29 
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staining in ECs (blue arrows). (panel aii, ×20) In tumor areas, TRPA1 expression is observed in all cases 
(n = 10/10) in ECs (blue arrows), with negative staining in tumor cells (red arrows). (panel bi, ×40) In 
histologically normal areas, TRPV2 expression is not observed in ECs (n = 0/10) (blue arrows) or 
epithelial cells (red arrows). (panel bii, ×40) Positive endothelial TRPV2 expression was observed in 7 
of 10 cases in the tumor areas (blue arrows), with positive staining in cancer cells in 4 cases (red 
arrow). TRPC3 expression: (panel ci, ×40) all normal tissues showed negative staining (n = 10/10) in 
ECs (blue arrows) with focal positive staining in epithelial cells (red arrow). (panel cii, ×10) Only one 
tumor (n = 1/10) showed faint positive TRPC3 staining on ECs (blue arrow), whereas cancer cells were 
positive (red arrows) in all cases. (panel di, ×20) TRPC6 expression was observed in ECs in 
histologically normal tissues (n = 6/10), (panel dii, ×40) whereas TRPC6 expression was absent in 
cancer cells in 7 out of 10 patient samples (red arrows). (b) Summary of endothelial and epithelial 
expression of the four ‘prostate-associated’ candidates in both normal and tumor areas for the ten 
patient samples used for immunohistochemical analysis. The patients were 62 to 70 years old, with 
PCa classified as ISUP group 2 in six cases and group 3 in four cases. Ca2+- imaging traces in response 
to TRPA1, TRPV2 and TRPC3 agonists respectively (c) 20 µM AITC), (d) 10 µM LPC and (e) 50 µM 
OAG in PTEC1 (black), PTEC2 (blue) and PTEC3 (red) but not in HPrMEC (green).Traces represents 
mean ± SEM of cells in the recorded field of one representative experiment. Lower panel: histogram 
showing peak amplitude of TRP agonist-mediated Ca2+ responses (mean ± 95% CI of different cells in 
the field from at least 3 independent experiments). Statistical significance and ****: p-value < 0.0001 
(Kruskal-Wallis test). 
As previously stated, we also identified trpc6 as a ‘prostate-associated’ downregulated gene. 
Immunohistochemistry for TRPC6 confirmed the qPCR data, as expression of the channel was 
observed in ECs in normal areas (n = 6/10) (Figure 2adi), while a negative staining was obtained in 
ECs in all tumor areas (n = 10/10) (Figure 2adii). TRPC6 expression was absent in cancer cells in 7/10 
Figure 2. Protein expression of ‘prostate-associated’ genes in PTEC and HPrMEC. (a) (panel ai, ×20)
TRPA1 expression in normal areas: focal positive staining in epithelial cells (red arrows) and diffuse
staining in ECs (blue arrows). (panel aii, ×20) In tumor areas, TRPA1 expression is observed in all cases
(n = 10/10) in ECs (blue arrows), with negative staining in tumor cells (red arrows). (panel bi, ×40)
In histologically normal areas, TRPV2 expression is not observed in ECs (n = 0/10) (blue arrows) or
epithelial cells (red arrows). (panel bii, ×40) Positive endothelial TRPV2 expression was observed in 7
of 10 cases in the tumor areas (blue arrows), with positive staining in cancer cells in 4 cases (red arrow).
TRPC3 expression: (panel ci, ×40) all normal tissues showed negative staining (n = 10/10) in ECs (blue
arrows) with focal positive staining in epithelial cells (red arrow). (panel cii, ×10) Only one tumor
(n = 1/10) showed faint positive TRPC3 staining on ECs (blue arrow), whereas cancer cells were positive
(red arrows) in all cases. (panel di, ×20) TRPC6 expression was observed in ECs in histologically
normal tissues (n = 6/10), (panel dii, ×40) whereas TRPC6 expression was absent in cancer cells in 7
out of 10 patient samples (red arrows). (b) Summary of endothelial and epithelial expression of the
four ‘prostate-associated’ candidates in both normal and tumor areas for the ten patient samples used
for immunohistochemical analysis. The patients were 62 to 70 years old, with PCa classified as ISUP
group 2 in six cases and group 3 in four cases. Ca2+- imaging traces in response to TRPA1, TRPV2 and
TRPC3 agonists respectively (c) 20 µM AITC), (d) 10 µM LPC and (e) 50 µM OAG in PTEC1 (black),
PTEC2 (blue) and PTEC3 (red) but not in HPrMEC (green).Traces represents mean ± SEM of cells in the
recorded field of one representative experiment. Lower panel: histogram showing peak amplitude
of TRP agonist-mediated Ca2+ responses (mean ± 95% CI of different cells in the field from at least 3
independent experiments). Statistical significance and ****: p-value < 0.0001 (Kruskal-Wallis test).
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As previously stated, we also identified trpc6 as a ‘prostate-associated’ downregulated gene.
Immunohistochemistry for TRPC6 confirmed the qPCR data, as expression of the channel was observed
in ECs in normal areas (n = 6/10) (Figure 2adi), while a negative staining was obtained in ECs in all
tumor areas (n = 10/10) (Figure 2adii). TRPC6 expression was absent in cancer cells in 7/10 patient
samples (Figure 2adii). However, PTEC showed variable expression of TRPC6 at the protein level,
as western blotting analysis showed no change in TRPC6 expression at the protein level in PTEC
relative to that in HPrMEC (Figure S2d).
Overall, except for TRPC3, the results obtained are consistent at the protein level and the mRNA
level determined by qPCR screening, thereby establishing ‘prostate-associated’ TRP channels as valid
candidates to study at the functional level by defining their role in TEC physiology. We have further
studied functional expression of TRPA1, TRPV2 and TRPC3 since up-regulation in mRNA and protein
levels do not necessarily correspond to increased channel activity. Ca2+ imaging experiments on the
three primary cells PTEC 1, 2 and 3 using the agonists of TRPA1 (Figure 2c), TRPV2 (Figure 2d) and
TRPC3 (Figure 2e) showed a significant increased Ca2+ influx as compared to HPrMEC in accordance
with the over-expression of these channels in PTECs.
2.3. ‘Prostate-Associated’ TRPV2 Enhances EC Viability
We functionally characterized the role of the three “prostate-associated” overexpressed TRP channels
(namely, trpa1, trpv2, and trpc3) in TECs. We first assessed the effect of the overexpression of the
selected TRP channels in cell viability, a key process in stalk cells during angiogenic sprouting [6,7].
For this purpose, we used HMECs as a cellular model to study the function and role of the selected
‘prostate-associated’ channels (trpa1, trpv2, and trpc3) since they exhibit a low or barely detectable
expression as shown by qPCR (Figure 1d). For all experiments, we verified the overexpression and
activity of the channels by western blotting and Ca2+ imaging experiments, respectively, using the
following channel activators: AITC for TRPA1; LPC for TRPV2; and OAG for TRPC3 (Figure S3).
Of the three TRP channels analyzed, only TRPV2 significantly increased basal HMEC viabiity by
approximately 55% relative to control cells, as evaluated by MTS assays (Figure 3a).
To study the functional role of the channels in PTEC, we immortalized PTEC (hTERT PTEC)
by retroviral transfection with telomerase reverse transcriptase (hTERT). To validate the new cell
model, we performed flow cytometric analysis to confirm endothelial markers expression (Figure S4a).
Similarly, to primary PTEC, hTERT PTEC expressed the following endothelial markers: Endoglin,
Type I membrane glycoprotein (CD105), Platelet EC adhesion molecule (CD31, PECAM-1), and Vascular
Endothelial Growth Factor Receptor1 (VEGFR1, Figure S4a). CD105 and CD31 expression was also
confirmed at the mRNA level by qPCR (Figure S4b). Phenotype maintenance was confirmed by flow
cytometry analysis of endothelial markers expression at passage 7 (Figure S4a). In addition, androgen
receptor (AR) expression was detected in hTERT PTEC (Figure S4e), as previously reported for primary
PTEC [18]. In line with this last study, hTERT PTEC cell lines were resistant to sorafenib (Figure S4d),
an anti-angiogenic drug currently used in the treatment of several cancers.
We further validated trp channel expression and function in hTERT PTEC as compared with PTEC3
(from which the cells were immortalized), HPrMEC and HMEC. Immortalized hTERT PTEC showed
equal expression of trpa1, trpv2, trpc3 and trpc6 as compared with PTEC3 cells (Figure 4a). hTERT PTEC
protein expression was validated by immunoblot and compared with HPrMEC (Figure 4b). Induction
of the endogenous TRPV2, TRPA1 and TRPC3/TRPC6 channels activity in PTEC was functionally
validated by Ca2+ imaging experiments. Stimulation of hTERT PTEC cells with the agonists of TRPA1,
TRPV2 and TRPC3 (20 µM AITC, 10 µM LPC and 50 µM OAG respectively) induced sustained Ca2+
influx and increased significantly the maximum amplitude of response in comparison with that in
HPrMEC, which barely express the channel proteins (Figure 4c).
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Figure 3. TRPV2 modulates EC viability. (a) The ‘prostate-associated’ channels were overexpressed
in HMEC to test their effect on cell viability. Of all channels, only TRPV2-overexpression positively
modulated proliferation in HMEC, 48 hours after transfection. Statistical significance *: p-value < 0.05
and **: p-value < 0.005 vs HMEC. (b) Treatment with the ‘prostate-associated’ channel agonists shows
that 10 µM LPC induces an increase in hTERT PTEC viability 48 h after treatment. Agonists were added
to the basal growth medium. Data represent the mean ± SEM of a minimum of three independent
experiments. Statistical significance ***: p-value < 0.005 vs. control basal medium. (c) Silencing of
TRPV2 expression significantly reduced hTERT PTEC viability, under both basal conditions and LPC
stimulation and reverted the LPC-induced increase in PTEC viability observed in control cells. Statistical
significance **: p-value < 0.005. (d) TRPV2 downregulation 48 h after siRNA transfection was verified
by western blotting in hTERT PTECs. Histogram showing the quantification of TRPV2 expression
relative to actin represented as the mean ± SEM of a minimum of three independent experiments.
(e) Downregulation of TRPV2 expression was also studied in Ca2+ imaging experiments 48 h after
siRNA transfection by stimulation with 10 µM LPC in control and TRPV2-silenced hTERT PTEC. Each
trace represents the ratio (340/380 nm) of a single cell in the field in one representative experiment.
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Figure 4. hTERT PTEC validation as cellular model for TEC studies. (a) Real-time qPCR analysis
validating equal amount of mRNA expression if trpa1, trpv2, trpc3 and trpc6 in hTERT PTEC compared
to PTEC1-3, as well as deregulated expression compared to HMEC and HPrMEC. Values are expressed
as the mean ∆∆CT values ± SEM of three independent experiments. (b) Representative immunoblots
blots (n = 3) showing similar TRPA1, TRPV2 and TRPC3, and TRPC6 expression in hTERT PTEC
compared to PTEC1, 2 and 3. B-actin was used as a loading control. (c) Ca2+- imaging traces in
response to TRPA1, TRPV2 and TRPC3 agonists respectively 20 µM AITC), 10 µM LPC and 50 µM
OAG in HMEC (red), HPrMEC (green) and hTERT PTEC (black). Traces represents mean ± SEM of all
cells in the recorded field of one representative experiment. Lower panel: histogram showing peak
amplitude of TRP agonist-mediated Ca2+ responses (median ± 95% CI of different cells in the field from
at least three independent experiments). Statistical significance *: p-value < 0.05, **: p-value < 0.005
and ****: p-value < 0.0001 (Kruskal-Wallis test.).
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Similarly HMEC stimulation with AITC and LPC show barely no Ca2+ responses; however OAG
promoted a significant increase in [Ca2+]i probably due to the non specific activity of OAG and possible
activation of TRPC6 (Figure 4c, Figure S4e). Altogether, these data show that hTERT PTEC are suitable
as a PTEC model for the study of the selected TRP candidates in cell processes important for EC
physiology, such as cell viability, migration, chemotaxis and tubulogenesis. We next assessed whether
the activation of the endogenous trpa1, trpv2, and trpc3 channels affected the viability of hTERT PTEC.
In line with the overexpression results in HMEC (Figure 3a), only treatment with 10 µM LPC (a TRPV2
agonist) induced an increase of approximately 45.5% in hTERT PTEC viability compared to that under
control conditions (Figure 3b), confirming the role of endogenous TRPV2 as a positive modulator of
EC proliferation. Silencing of TRPV2 expression significantly reduced availability in hTERT PTEC,
under both basal conditions and LPC stimulation (Figure 3c). The role of TRPV2 in cell proliferation
was confirmed by means of BrDU assay (Figure S4f). Downregulation of TRPV2 expression was
verified by Ca2+ imaging experiments 48 hours after siRNA transfection after stimulating control and
TRPV2-silenced (siTRPV2) hTERT PTEC with 10 µM LPC (Figure 3e,f). Mean TRPV2 downregulation
of 44.3% was verified 48 hours after siRNA transfection by means of western blotting (Figure 3d).
2.4. ‘Prostate-Associated’ TRPA1 Expression Promotes EC Migration
Cell migration is one of the key steps involved in sprouting angiogenesis that enables endothelial
tip cells to function as motile guidance structures that dynamically extend filopodia to explore signals
in the tumor microenvironment for directional vessel growth [21]. We thus investigated the role of the
four ‘prostate-associated’ channels in EC migration. For this purpose, we overexpressed the channels
in HMECs to analyze their effect on EC motility by means of scratch wound healing assays. Among
the three candidates, overexpression of TRPA1 significantly increased migration in HMEC compared
to that in non-transfected cells (Figure 5a). The increase in migration rate was significant from 2 h
onward and peaked after 8 hours in TRPA1-overexpressing HMEC compared to that in control cells.Cancers 2019, 11, x 11 of 29 
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Figure 5. TRPA1 increases E igration. (a) The ‘prostate-associated’ channels were overexpressed in
HMECs to test their effect on cell migration. Expression of TRPA1 increased the migration of HMEC
relative to control cells in basal medium, as observed by wound healing experiments. Lines show the
mean value ± SEM of one out of three independent experiments (24 h after transfection). Statistical
significance **: p-value < 0.005 and ***: p-value < 0.0005 vs. HMEC. (b) Histogram showing the %
migration in wound healing experiments of PTEC transfected with control siRNA (siCNTRL) or siRNA
against TRPV2 (siTRPV2), under both basal conditions and 8 h after treatment with TRPA1 inhibitor
HC030031. Statistical significance **: p-value < 0.005 and ***: p-value < 0.0005 vs. HMECs. (c) TRPA1
downregulation 48 h after siRNA transfection was verified by western blotting. Histogram shows
quantification of TRPA1 expression relative to actin represented as the mean + SEM of a minimum
of three independent experiments. *: p-value < 0.05. (d) Do nregulation of TRPA1 expressi n was
verified 72 h after siRNA transfection in Ca2+ imaging experiments by stimulation with 20 µM AITC in
control PTEC (siCNTRL, black trace) and in PTECs transfected with siRNA against TRPA1 (siTRPA1,
red trace). (e) TRPA1 activity is inhibited when PTEC are treated with a TRPA1 channel inhibitor (20 µM
HC030031) based on Ca2+ imaging experiments. For experiments in c, d and e traces show the mean
value ± SEM of all cells in the recorded field of one represen ativ experiment (left panel); histograms
represent the quantification of the peak amplitude after treatment with AITC (c,d) or different doses of
the channel inhibitor (10 or 20 µM HC030031) in Ca2+ imaging experiments (e, right panel).
We further investigated th e dogenous role of TRPA1 in hTERT PTEC motility, as this channel i
strongly up r gulated in PTEC co pa d to tha in normal ECs (Figures 1 and 2). To achieve this goal,
we tested the effect of TRPA1 silencing in hTERT PTEC by wound healing experiments (Figure 5b).
Compared to siCNTRL transfection, down regulation of TRPA1 expression in PTEC by means of siRNA
transfection induced a significant decrease of 23% in cell migration (siTRPA1) (Figure 5b). Moreover,
TRPA1 inhibition by treatment with the channel inhibitor (20 µM HC030031) induced a 41% decrease
in migration in control hTERT PTEC (siCNTRL) but not in TRPA1-silenced hTERT PTEC (siTRPA1)
(Figure 5b). Next, endogenous functional expression of TRPA1 in hTERT PTEC and HMEC was
tested by Ca2+ imaging. [Ca2+]i significantly increased in hTERT PTEC but not in HMEC following
stimulation with the TRPA1 channel agonist AITC (20 µM) (Figure 5d). On the other hand, silencing of
TRPA1 expression in hTERT PTEC significantly reduced AITC-mediated [Ca2+]i by 3.26-fold (Figure 5d).
Similarly, treatment with two different concentrations (10 µM and 20 µM) of the TRPA1 inhibitor
HC030031 dramatically decreased AITC-induced channel activity in hTERT PTEC (Figure 5e). Mean
TRPA1 downregulation of 36.8% was verified via western blotting in PTEC 48 h after siRNA transfection
(Figure 5c).
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2.5. ‘Prostate-Associated’ TRPC3 Promotes PCa Cell Attraction
TECs have been shown to exert a chemoattractive effect on cancer cell, thus guiding cancer
metastasis [22]. We thus considered a possible role of the three ‘prostate-associated’ channels that are
upregulated in PTEC (trpa1, trpv2 and trpc3) in the cross-talk between TECs and PCa cells. In this
regard, we showed that hTERT PTEC exert a significantly stronger attractive effect on PCa cells (PC3)
in co-culture experiments than do normal ECs (HMEC) (Figure 6a). Moreover, we overexpressed
TRPA1, TRPV2 and TRPC3 channels in HMEC and investigated the effect on PC3 cell attraction. TRPC3
overexpression in HMEC induced a significant increase of 219% in PC3 cell attraction compared to that
in control cells, mimicking the effect of PTEC that endogenously overexpress the channel (Figure 6a).
However, TRPA1 and TRPV2 overexpression in HMECs did not alter PC3 cell attraction compared to
that in control HMEC in co-culture experiments (Figure 6a central panel), supporting a specific role for
TRPC3 in PCa cell attraction.
We further explored the role of TRPC3 in PCa cell attraction by chemoattraction assays in
the presence of hTERT PTEC, TRPC3-overexpressing HMEC, or control HMEC conditioned media
(Figure 6b). We observed that compared to HMEC conditioned medium, hTERT PTEC conditioned
medium (24-h conditioning) increased PC3 cell migration speed (Figure 6b,c, left panel). Moreover,
compared to control HMEC conditioned media, the conditioned medium from TRPC3-overexpressing
HMEC significantly promoted PC3 migration via enhancing the directional persistence index but
not the speed (Figure 6b,c, central and right panels). These data, together with the results from the
transwell migration experiments, confirm that TRPC3 expression is correlated with PCa cell attraction
by TECs.
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Figure 6. 3 has a role in PCa cell attraction. (a) PC3 cells were used to study the effect of
TRPA1, TRPV2 and TRPC3 on cancer cell attraction. Control HMEC, channel-overexpressing HMEC
or hTERT PTEC were plated in multiwell plates, and PC3 cells were plated in the upper chamber
of 8 µm-pore culture inserts. hTERT PTEC or TRPC3-overexpressing HMEC (HMEC C3) increased
PC3 cells migration through the membrane, quantified 24 h after plating. Each dot indicates the cell
number in a single field normalized to PC3 cell count; results are presented as normalized values
against co-cultured HMEC, while the continuous line represents the median value of normalized
cells/field for each condition (n = 10). The graph shows one representative experiment out of three.
Statistical significance: ** p-value < 0.005; *** p-value < 0.0005. Right panel shows the schematic
representation of the migration assays used to study PC3 cell migration in co-culture with either hTERT
PTEC, TRPA1/V2/C3-overexpressing HMEC, or control HMEC. (b) Chemotaxis chambers were used
to study hTERT PTEC-directed migration in the presence of hTERT PTEC-, TRPC3-overexpressing
HMEC-, HMEC- or non-conditioned (non-cond) media. Compared to HMEC conditioned medium,
PTEC conditioned medium (24-h conditioning) increased PC3 cell speed (c, left panel), while compared
to control HMEC conditioned medium, the conditioned medium from TRPC3-overexpressing HMECs
significantly promoted PC3 migration via directional persistence index and not on the speed (c, central
and right panels). Statistical significance: * p-value < 0.05, ** p-value < 0.005 and *** p-value < 0.0005.
2.6. TRPA1 Promotes Vascular Network Formation and Angiogenic Sprouting both In Vitro and In Vivo
The results described above indicate that TRPA1 is a modulator of PTEC migration, raising the
question of whether this channel also affects tubulogenesis or in vivo angiogenesis. To investigate
this point, we tested TRPA1 and other TRP candidates for their ability to organize into capillary-like
structures in vitro. Interestingly, among all the ‘prostate-associated’ channels, a significant increase in
the capillary-like structure formation was observed in TRPA1-overexpressing HMEC relative to that in
control cells (Figure 7a, Figure S5). In particular, for TRPA1 overexpression, we observed a strong and
significant increase in the number of master segments and a concomitantly significant decrease of number
of isolated segments, two important parameters of EC organization during network formation (Figure 7a,
right panel). The role of endogenous TRPA1 was subsequently studied on hTERT PTEC capillary-like
structure formations: both TRPA1 inhibitor HC030031 treatment or TRPA1 down regulation strongly
and significantly decreases the number of master segments and a significantly increase the number of
isolated segments (Figure 7a, right panels). These results suggest that in addition to playing an important
role in cell migration, TRPA1 exerts a marked effect on in vitro EC morphogenesis, which is one of the
key features required for new vessel formation (Figure 7a).
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To further confirm the role of TRPA1 in vessel morphogenesis, we performed in vivo experiments
by using the well-established in vivo angiogenesis model of postnatal mouse retina. Endogenous
TRPA1 is diffusely expressed in postnatal mouse retina but clearly co-localizes with CD31 staining,
indicating that TRPA1 is expressed in ECs (Figure 7b). Moreover, TRPA1 expression was detected
by qPCR in CD31-positive cells isolated from the whole retina, confirming its expression in retinal
ECs (Figure 7c). Subretinal injection of AITC or HC030031 did not alter the overall development
of the vascular plexus 3 days after treatment but disturbed the vascular front. Indeed, the front of
the growing vasculature appeared more uneven after injection of the TRPA1 agonist AITC in the
subretinal space. This was illustrated by a significant increase of 26.8% in the length of the sprouts
(Figure 7e, upper graph, white bars). In addition, when vascular sprouts were counted and classified
in terms of their length (<70 µm, 70–150 µm or >150 µm), the number of longer sprouts (>70 µm) was
increased after AITC injection (Figure 7f), confirming the irregular growth front of the retinal vascular
plexus when TRPA1 is activated. In contrast, the retina vascular front was straighter when the TRPA1
inhibitor HC030031 was injected in the vitreous, confirmed by a 14.1% reduction in the length of the
vascular sprouts (Figure 7e, lower graph, white bars) and by an increase in the number of the shorter
sprouts (<70 µm) and a decrease in the number of longer sprouts (Figure 7f, lower panel). These data
demonstrate an important role of TRPA1 in vascular remodeling (as demonstrated by capillary-like
morphology in Matrigel), as well as in vascular sprouting in vivo in the retina. Therefore, we detected
an important role of TRPA1 (Figure 7a) by overexpression or inhibition of its basal activity using the
TRPA1 blocker HC030031, (Figure 7d) further supporting the role of TRPA1 in vascular remodeling.
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The significant role of TRPA1 in sprouting angiogenesis intrigued us to evaluate a possible activity
of this channel in chemoattraction. In order to verify this hypothesis, we performed migration transwell
assays stimulating hTERT PTEC cells in the presence of 20 µM AITC in the lower compartment.
Figure 8 clearly shows a chemoattractive effect in cell stimulated with TRPA1 agonist as compared to
control (Figure 8a). We next evaluated whether this chemoattractive role was due to specific activation
of TRPA1 on migrating cells.
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For this purpose we performed Ca2+ imaging experiments on hTERT PTEC forming capillary-like
structures. Interestingly we observed a specific distribution of TRPA1 activity in hTERT PTEC plated
on Matrigel/collagen substrate as compared to 2D culture dishes (Figure 8b). 20 µM AITC induced
a strong increase in [Ca2+]i only in cells engaged in migration (here called “tip-like” cells to recall
“tip” cell organization in vessel morphogenesis, Figure 8b,c). These data are in agreement with the
role of TRPA1 in vessel morphogenesis and cell migration suggesting an active role for the channel in
sprouting angiogenesis and tip cells activation.
3. Discussion
The present study provides a full TRP channel expression signature in TECs from PCa by shedding
light on their expression profile and the role of the most prominent TRP channels in tumor angiogenesis.
We identified four ‘prostate-associated’ genes (i.e., trpa1, trpv2, trpc3, and trpc6), which were deregulated
in previously isolated and characterized PTEC [18] compared to those in ECs derived from the
healthy prostate. Among them, three ‘prostate-associated’ channels (TRPA1, TRPV2, and TRPC3) were
overexpressed during PCa angiogenesis and showed proangiogenic activity by exerting effects on the
principal EC properties during angiogenesis, particularly EC proliferation, to support sprout formation,
directed motility guiding, sprout elongation and in vitro and in vivo morphogenesis regulation.
The study of global changes in trp channel expression patterns during physiopathological
transitions and disease progression is important for understanding the development of many
pathologies, such as cancer [16]. Moreover, a molecular trp signature of a particular cancer could
represent a promising prognostic tool for several cancer types. In this regard, several studies have been
recently performed, and microarray-assisted expression profiling has identified several ion channel
genes (including trp channels) to be differentially expressed in tumor tissues relative to those in normal
tissues and to contribute to various extents to pathophysiological hallmarks in breast cancer [23],
lung adenocarcinoma [24], glioma [25] or pancreatic ductal adenocarcinoma [26].
Here, we show that TRPV2 is a positive modulator of TEC viability, since LPC-mediated activation
of endogenous TRPV2 in PTEC resulted in increased viability and proliferation, and downregulation
of the channel by siRNA transfection reverted this effect. These data underline a basal role for
TRPV2 even in the absence of agonist stimulation. We confirm the different patterns of trpv2 mRNA
expression obtained by qPCR in PCa vessels by immunohistochemistry on tissues obtained from
radical prostatectomies in patients (7 cases out of 10). Even though TRPV2 transcript expression has
been reported in human pulmonary artery [27] and umbilical vein [28] ECs, its role in these cells is not
described. In circulatory organs, TRPV2 is mainly expressed in smooth muscle cells and participates in
mechanosensation [28]. Our study showed, for the first time, a role for TRPV2 in tumor angiogenesis
by clearly demonstrating the channel as a positive modulator of EC viability and proliferation. TRPV2
has been previously indirectly implicated in angiogenesis since activation of the channel in fibroblasts
by its synthetic cannabinoid agonist (O-1821) was correlated with altered angiogenesis in a mouse
model of arthritis [29]. The proangiogenic role we described here for TRPV2 adds another aspect to
the tumorigenic properties of TRPV2, since this channel has been positively correlated with tumor
progression to the castration-resistant phenotype in PCa [11] and with tumor grade and stage in
bladder cancer [30]. In both these urogenital cancers, basal and agonist-induced activity of TRPV2
increased the migratory potential of cancer cells. Lysophospholipids and adrenomedullin stimulate
insertion of the channel into the plasma membrane, and the subsequent TRPV2-mediated Ca2+ influx
increases invasiveness of tumor cells via the direct regulation of key proteases such as MMP2, MMP9,
and cathepsin B [11,31,32]. However, in this study, we demonstrated that TRPV2 activation can result
in different physiological effects depending on the cell type, since activation of endothelial TRPV2
enhanced cell proliferation rather than cell motility. Because agonists of TRPV2 are implicated not only
in tumor progression but also in angiogenesis [33–36], we can speculate that TRPV2 activity could
be targeted in both TECs and normal ECs. The use of TRPV2 as an antitumor target is certainly an
exciting prospect in drug research but should be considered with caution for cancers other than PCa.
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The tumor microenvironment, including the vascular endothelium, plays a critical role in the
different phases of tumor progression leading to invasion. The crosstalk between cancer cells and
ECs is therefore crucial for both angiogenesis and cancer invasion. Several studies have reported the
importance of endothelial-mediated release of growth factors in cancer chemoattraction. In this regard,
TECs have been shown to exert a chemoattractive effect on cancer cells, thus guiding cancer cell
metastasis in different cancer types [22,37,38]. In line with this, in directed migration experiments,
we demonstrate that compared to normal HMEC, PTEC have a strong effect on PCa cell attraction.
Our results indicate that this effect may be due to the expression of TRPC3, which is maintained at
high levels in PTEC and downregulated in HMECs. Consistent with this observation, TRPC3 (but
not TRPA1 or TRPV2) overexpression in HMEC induced an increase in cell attraction compared to
that in control cells. Additionally, PTEC conditioned medium but not HMEC conditioned medium
attracted PC3 in directional migration experiments. Moreover, similarly to PTEC conditioned medium,
conditioned medium from TRPC3-overexpressing HMECs promoted directional migration of PC3
cells. Although the molecular mechanism underlying EC-driven crosstalk with cancer cells has not
been elucidated and requires further studies, we can speculate that TRPC3-mediated Ca2+ signaling in
TECs may promote the release of growth factors or chemokines, which in turn promote cancer cell
migration, as Ca2+ signals are known as key players in EC activation in the tumor microenvironment,
one of the most relevant steps in tumor progression [4,39].
Finally, we demonstrate that TRPA1 is an important positive modulator of vessel morphogenesis,
activating sprouting angiogenesis in vivo and EC migration and tubulogenesis in vitro. We show
that endogenous TRPA1 increased wound healing in PTEC and that this effect was inhibited with
the downregulation of the channel by siRNA transfection. In line with this, TRPA1 overexpression
in HMECs increased cell migration and tubulogenesis in vitro. Most importantly, TRPA1 activation
increased angiogenesis in mouse retina, while pharmacological inhibition of TRPA1 caused a decrease
in the number of retinal tip cells. Interestingly, the role of Ca2+ signals in sprouting angiogenesis
has been recently reported in vivo in a zebrafish model [40]. Yokota and coworkers visualized Ca2+
dynamics in ECs during sprouting angiogenesis in zebrafish, demonstrating that intracellular Ca2+
oscillations occur in ECs exhibiting angiogenic behavior. Dll4/Notch signaling regulates these Ca2+
oscillations and is required for the selection of stalk and tip cells during both arterial and venous
sprouting [40]. Although whether Dll4/Notch signaling regulates Ca2+ stores or Ca2+ channels directly
or not remains to be delineated, our study suggests TRPA1 as a possible mediator of this pathway,
as its activation is clearly involved in vessel sprouting in vivo. In line with these observations we
have shown here that TRPA1 agonist induced a strong increase in [Ca2+]i only in cells engaged in
migration which we could call “tip-like” cells to recall “tip” cell organization in vessel morphogenesis.
These data suggest an active role for the channel in sprouting angiogenesis and tip cells activation.
Moreover endothelial TRPA1, it has been previously shown to be selectively expressed in cerebral
arteries where it plays a role in vasodilation [41]. Indeed, Ca2+ influx via endothelial TRPA1 channels
elicits vasodilation in cerebral arteries by a mechanism involving Ca2+-activated K+ channels and
inwardly rectifying K+ channels in rat myocytes [42]. TRPA1 has also been recently shown to be
involved in PCa growth, as its activation by triclosan, a well-established endocrine disruptor, resulted
in cytosolic Ca2+ influx inducing VEGF secretion by stromal cells, which in turn stimulated epithelial
cell proliferation [43]. Moreover, TRPA1 activation by resveratrol induces Ca2+ entry, leading to growth
factor expression, possibly via the Calcineurin/NFAT pathway, and secretion of HGF and VEGF, which
modulate PCa cell growth, migration and resistance to apoptosis [44].
In summary, we performed a complete expression profiling and functional screening that clearly
identified four ‘prostate-associated’ genes that are deregulated during PCa vascularization, three of
which play profound effects on EC biology. In particular, three out of the selected ‘prostate-associated’
channels are overexpressed in PCa ECs and have marked effects on the main EC properties including
proliferation (TRPV2), TEC-mediated crosstalk with cancer cells (TRPC3) and angiogenesis (TRPA1).
The expression profile and functional data could indeed explain the specific transition of PCa to its
Cancers 2019, 11, 956 19 of 29
aggressive phenotype. PTEC have been previously shown to exhibit aggressive phenotypes typical
of TECs: indeed, PTEC have a higher migration rate than normal HMECs and are able to form
capillary-like structures both in vitro and in xenografts in SCID mice [18]. These results could be of
great importance to explain, at least part, the aggressive phenotype previously observed in PTEC
relative to that in normal HUVEC and HMEC [18] and provide new putative therapeutic targets.
4. Materials and Methods
4.1. Chemicals and Drugs
Naltriben methanesulfonate hydrate (NTB), was resuspended in DMSO to a final concentration
of 25 mM and stored at −20◦C, according to the manufacturer’s instructions. Allyl isothiocyanate
(AITC) was diluted in DMSO to a final concentration of 10 mM and stored at −20 ◦C, according to the
manufacturer’s instructions. L-α-Lysophosphatidylcholine from soybean (LPC) was diluted in ethanol
to a final concentration of 20 mM and stored at −20 ◦C, according to the manufacturer’s instructions.
1-Oleoyl-2-acetyl-sn-glycerol (OAG) was diluted in DMSO to a final concentration of 100 mM and stored
at −20 ◦C, according to the manufacturer’s instructions. All drugs were purchased from Sigma-Aldrich
(St Louis, MO, USA). Fura2-AM calcium probe used in calcium imaging experiments was purchased
from (Invitrogen Ltd., Waltham, MA, USA) and dissolved in DMSO to a final concentration of 1 mM
and stored at −20 ◦C.
4.2. Cell Cultures and Transfection
Normal glomerular ECs (GEC), breast tumor ECs (BTEC), renal tumor ECs (RTEC) were isolated
and characterized as described by Bussolati et al. [19,20,45]. Prostate tumor ECs (PTEC) primary
cultures were isolated and characterized as previously described [18]. Normal human prostatic
microvascular ECs (HPrMEC) were purchased from ScienCell Research Laboratories (Carlsbad, CA,
USA). HMECs were obtained from the derma using an anti-CD31 antibody and MACS. HMECs
from the derma were immortalized by the infection of primary cultures with a replication-defective
adeno-5/SV40 virus as previously described [46,47]. All endothelial cells were cultured in EndoGRO
MV-VEGF medium (Merck Millipore, Darmstadt, Germany) containing 5% fetal bovine serum (FBS).
All cell cultures were maintained in incubator (37 ◦C and 5% CO2 atmosphere), using Falcon™
plates as supports (about 5000 cells/cm2) and were used at passage 3 to 12 (for HMEC, GEC, BTEC,
and RTEC) or at passage 1 to 5 (for HPrMEC and PTEC). TECs (BTEC, RTEC and PTEC) were
cultured on coating of 1% gelatin. When specified, experiments were performed using DMEM,
Dulbecco’s modified eagle medium (Sigma-Aldrich), with 4500 mg/L glucose, 15 mM HEPES and
sodium bicarbonate. DMEM was supplemented with 2% L-glutamine, 0.5% gentamicin, and 0, 2,
or 10% FBS. HMEC cells were transfected with NucleofectorTM (Amaxa, Gaithersburg, MD, USA) for
Human Primary Endothelial Cells with 2 µg of each construct: human pcDNA3TRPA1 [43], human
pcDNA3TRPV2 [11], human pcDNA3.1TRPC3 (Addgene, Watertown, MA, USA plasmid #25902),
human pcDNA3TRPC6 (already present in our laboratory), mouse pcDNA3.1TRPM7 (kind gift from
Prof. Thomas Guderman). Control experiments were performed by transfecting the empty vector.
For siRNA-mediated silencing, PTEC were plated in six-well dishes at a concentration of 6 × 104
cells per well (3 wells/condition) the day before oligofection. Oligofection (Oligofectamine, Thermo
Fisher Scientific, Waltham, MA, USA) of siRNA duplexes was performed according to manufacturer’s
protocol. Briefly, PTEC were transfected twice (at 0 and 24 h) with 200 pmol siLuc (control, siCNTRL),
siTRPA1 or siTRPV2. siRNA against Luciferase (siLuc; Eurogentec, Seraing, Belgium) was used for
control silencing. 24 or 48 h after the second oligofection, PTEC were lysed or tested in functional
assays. The siTRPA1 sequence is 5′-GGUGGGAUGUUAUUCCAUA(dTdT)-3′ [43], and the siTRPV2
sequence is 5′-UAAGAGUCAACCUCAACUAdTdT (dTdT)-3′ [32].
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4.3. Generation of Immortalized PTEC
Primary prostate-derived TEC (PTEC) were infected (at passage 2) with a retrovirus containing a
pBABE-puro-hTERT plasmid (Addgene plasmid #1771) [48] and selected using the antibiotic resistance
(1 µg/mL puromycin, Gibco, Thermo Fisher Scientific, Waltham, MA, USA) for two weeks. hTERT
mRNA was always upregulated in hTERT PTEC as compared with wild type PTEC, as shown in
Figure S4c.
4.4. Flow Cytometry
hTERT PTEC were detached from plates with a non-enzymatic cell dissociation solution
(Sigma-Aldrich), washed and stained (30 min at 4 ◦C) with the following fluorescein isothiocyanate
(FITC)-, phycoerythrin (PE)-, or allophycocyanin (APC)-conjugated antibodies: CD31 (BD Bioscience,
Franklin Lakes, NJ, USA), CD105 (from MiltenyiBiotec, Bergisch Gladbach, Germany), VEGFR1 (R&D
Systems, Minneapolis, MN, USA). Isotypes (all from MiltenyiBiotec, Bergisch Gladbach, Germany)
were used as negative controls. Cells were subjected to cytofluorimetric analysis (FACScan Becton
Dickinson, Franklin Lakes, NJ, USA) every other passage.
4.5. In Vivo Angiogenesis
Wild type outbred OF1 mice were purchased from Charles River (Wilmington, MA, USA).
Sub-retinal injections were performed in three-day-old anesthetized mice by injecting 0.5 µL DMSO
(control), 500 µM AITC or 500 µM HC030031. Six-day-old mice were sacrificed by decapitation
according to the CNRS recommendation and eyes were enucleated. Retinal cups were dissected
under binoculars and briefly fixated using 4% PFA in PBS before whole mount immunostaining.
Flat mount retinas were incubated overnight at 4 ◦C with the rabbit anti-mouse type IV collagen
(ab6586, 1 mg/mL, 1:500, Abcam, Cambridge, UK). After washes, retinas were then incubated with the
fluorescent secondary antibody donkey anti-rabbit A594 (Invitrogen, 2 mg/mL, 1:500). Retinas were
finally washed and mounted in Mowiol before imaging with an AxioImager Z1-Apotome (Carl Zeiss,
Marly le Roi, France). All pups derived from a litter were used in one experiment. Experiments
were performed two times with six retinas per treatment. The distances between the established
retina vascular plexus and the extended vascular sprouts were measured for each condition. VM was
authorized to perform experimentation on animals (#59-35066) and experimental procedure has been
deposited to Ministère de l’enseignement supérieur et de la Recherche (French government research
department), as per regulations.
4.6. Isolation of CD31 Positive Cells from Retinas
Retinas were harvested from six-day-old mouse pups previously sacrificed by decapitation.
Retinas were digested with type I collagenase (2 mg/mL, Life Technologies) and DNAse I (10 µg/mL,
Roche Life Science, New York, NY, USA) in DMEM for 40 min. Cell suspensions were then incubated
with 25 µL magnetic beads (Dynabeads Sheep anti-Rat IgG, Life Technologies) previously coated
with 1.5 µg anti-CD31 antibody (rat anti-mouse CD31, Becton Dickinson). CD31+ cells were isolated
following manufacturer’s instructions. Isolated cells were centrifuged and suspended in Trizol for
total RNA isolation and RT-qPCR analysis.
4.7. Patients and Tissues
Formalin-fixed paraffin-embedded tissue samples containing both normal and tumor areas were
obtained from 10 patients treated by radical prostatectomy for prostate cancer. Patients were aged
62 to 70 years old, with PCa classified as ISUP group 2 in 6 cases and group 3 in 4 cases. Serial 3 µm
sections of the paraffin blocks were used for immunohistochemistry. Written informed consents were
obtained from patients in accordance with the requirements of the medical ethic committee, Comité de
Protection des Personnes of Tours Universitary Hospital of the 18th of February (DC-2014-2045).
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4.8. Immunohistochemistry
Slides were deparaffinized, rehydrated, and heated in citrate buffer pH 6 for antigenic retrieval.
After blocking for endogenous peroxidase with 3% hydrogen peroxide, the following antibodies
were incubated: TRPA1 (#ACC-037 1:500, 1 h, Alomone Labs, Jerusalem, Israel), TRPV2 (SAB1101376
Sigma, 1:1000, 1 h), TRPC3 (#ACC-016 Alomone, 1:500, 1 h), TRPC6 (#ACC-017 Alomone, 1:300,
1 h). Immunohistochemistry was performed using the streptavidin-biotin-peroxidase method with
diaminobenzidine as the chromogen (Kit LSAB, Dakocytomotion, Glostrup, Denmark). Slides were
finally counterstained with haematoxylin. Negative controls were obtained after omission of the
primary antibody or incubation with an irrelevant antibody. For cryo-sections, retinas were fixed
overnight with 4% PFA, rinsed in PBS and then incubated with 30% sucrose before OCT embedding.
Retina sections were blocked and permeabilized in PBS 0.25% triton, 5% FBS, 1% BSA for 2 h and
incubated overnight at 4 ◦C with the rabbit anti-TRPA1 antibody (#ACC-037 Alomone, 1:100) and
the rat anti-CD31 (Becton Dickinson, 1/100). After washes, sections were incubated with secondary
antibody donkey anti-rabbit A488 and donkey anti-Rat A594 for 2 h at room temperature. Sections
were then washed and stained with DAPI before mounting in Mowiol. Sections were imaged with a
Carl Zeiss AxioImager Z1-Apotome.
4.9. Total RNA Extraction and Reverse Transcription
Total RNAs were extracted from cultured cells by Nucleospin RNA II kit (Clontech Laboratories,
Mountain View, CA, USA) according to manufacturer’s protocol, and subjected to reverse transcription
as previously described [49].
4.10. Quantitative Real-Time PCR
Real-time qPCR of cDNA was done using qPCR SsoFast™ EvaGreen® Supermix (Bio-Rad,
Hercules, CA, USA) on the CFX96 Real-Time PCR Detection System (Bio-Rad). The primers for trp
channels were designed on the functional region of the channels using Primer3 software (PREMIER
Biosoft, Palo Alto, CA, USA) and efficiency was validated on trp-coding plasmids and cell lines
expressing the channels (Table 1).
The sequences for the actin and hprt primers are: 5′-CAGCTTCCGGGAAACCAAAGTC-3′
and 5’-AATTAAGCCGCAGGCTCCACTC-3′ for 18s; 5′-GGCGTCGTGATTAGTGATGAT-3′ and
5′-CGAGCAAGACGTTCAGTCCT-3′ for hprt. For the qPCR on cDNA from mice retina the
following primers were used: 5′- GCAGGTGGAACTTCATACCAACT-3′ and 5′-CACTTTGCGTAAGTA
CCAGAGTGG-3’ for trpa1; 5′-CTGCAGGCATCGGCAAA-3′ and 5′-GCATTTCGCACACCTGGAT-3’
for CD31; 5’-GCCATGGATGACGATATCGCTG-3′ and 5′-GCCATGGATGACGATATCGCTG-3′ for
actin. 18s and hprt (hypoxanthine-guanine phosphoribosyltransferase) were used as internal controls
to normalize variations in RNA extraction and RT efficiency. In order to quantify relative gene expression
(Figure 1d, Figure S1a,c,d), the delta-delta Cycle threshold (∆∆CT) method was used, calculating the
difference between the normalized expression values of tumor and normal samples: 2−∆∆CT , where
∆∆Ct = (∆CT target gene, tumor – ∆CT re f gene, tumor)−
(
mean ∆CT target gene, normal – mean ∆CT re f gene, normal
)
.
In dispersion graphics (Figure 1e), values are expressed as mean Log10 (
CT, target gene
CT, 18s
) of at least three
independent experiments. All screened ECs did not show differences in the expression of the two internal
controls used for the screening, 18s and hprt (Figure S1a), showing that there were no significant variations
in the amount of input cDNA that could interfere with the differential profiling. Prior to the definition
of the TEC differential profile, we had to assess the correct healthy counterpart to be used for PTEC. We
therefore plotted the mRNA expression of two normal EC cell lines, namely dermal HMEC and prostatic
HPrMEC, of the different trp channels (expressed as the Logarithm of the corrected qPCR threshold cycle
(CT) values). As shown in Figure S1b, the values are very poorly correlated: most of the values of HMEC
are stable in contrast to the values of HPrMEC, showing the necessity of a prostate specific EC model as
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healthy counterpart for our studies. In light of these results, we decided to use HPrMEC as the healthy
counterpart of PTEC.
Table 1. Primers for trp channels were designed on the functional region of the channels. Primer3 was
used to select the best primer couple for each gene. Primer couples were chosen in order to detect all
functional variants described in NCBI.
TRP Channel PCR Product Length (nt)
Gene NCBI Reference Sequence
trpv1 NM_080704.3 101
trpv2 NM_016113.4 94
trpv3 NM_001258205.1 118
trpv4 NM_021625.4 99
trpv5 NM_019841.6 114
trpv6 NM_018646.5 118
trpc1 NM_001251845.1 118
trpc3 NM_001130698.1 112
trpc4 NM_016179.2 90
trpc5 NM_012471.2 111
trpc6 NM_004621.5 95
trpc7 NM_020389.2 110
trpm1 NM_001252020.1 91
trpm2 NM_003307.3 100
trpm3 NM_020952.4 113
trpm4 NM_017636.3 93
trpm5 NM_014555.3 117
trpm6 NM_017662.4 117
trpm7 NM_017672.5 109
trpm8 NM_024080.4 113
trpa1 NM_007332.2 95
trpp2-pkd2 NM_000297.3 110
trpp3-pkd2l1 NM_016112.2 110
trpml1-mcoln1 NM_020533.2 117
trpml2-mcoln2 NM_153259.3 91
trpml3-mcoln3 NM_018298.10 96
4.11. Western Blot
Conditions for SDS–PAGE and western blotting were as previously described [8]. Polyvinylidene
fluoride membranes were properly blocked in 5% bovin sieric albumin (BSA) in TNT buffer (0.1 M
Tris-Cl pH 7.5, 150 mM NaCl, 0.1% Tween-20) for 30 s and then incubated over night with anti-TRPA1
(#ACC-037, Alomone, 1:200), anti-TRPC3 (#ACC-016, Alomone, 1:500), anti-TRPC6 (#ACC-017,
Alomone, 1:200), or anti-TRPV2 (SAB1101376, Sigma, 1:500), anti-β-actin (A5316, Sigma, 1:1000)
primary antibodies, following manufacturer’s instructions. The membrane was then washed using
TNT containing 0.1% Tween 20 and incubated with the appropriate HRP-conjugated secondary
antibodies (SantaCruz, Dallas, TX, USA). Membranes were treated with either Femto or Dura enhanced
chemiluminescence (ECL) reagents (ThermoFisher, Thermo Fisher Scientific, Waltham, MA, USA) for 1
or 5 min respectively, and exposed by Amersham Imager 600 (GE Healthcare, Little Chalfont, UK).
To quantify the differences in protein expression, the ratio between TRP channels and actin expression
was evaluated using Fiji, ImageJ software (https://imagej.net/Fiji). Whole scans of the immunoblots
were shown in Figures S6 and S7.
4.12. Calcium Imaging
Cells were seeded on gelatin-coated glass coverslips at a density of 5000 cells/cm2 at 24 h before the
experiments. Cells were starved in DMEM 5% FBS for at least 2 h before the experiments. Cells were
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next loaded (45 s at 37 ◦C) with 2µM Fura-2 AM, for ratiometric cytosolic calcium concentration ([Ca2+]i)
measurements. During experiments, cells were maintained in standard extracellular solution of the
following composition: 154 mM NaCl, 4 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 5 mM HEPES, 5.5 mM
glucose. Solution pH was adjusted to 7.35 using NaOH. 4 h before experiments cells were starved in
DMEM 2% FBS. Fluorescence measurements were made using a Polychrome V spectrofluorimeter
(TILL Photonics, Munich, Germany) attached to an Olympus ×51 microscope (Olympus, Tokyo, Japan)
and Metafluor Imaging System (Molecular Devices, Sunnyvale, CA, USA). [Ca2+]i was measured using
ratiometric probe Fura-2-AM and quantified according to Fiorio Pla et al. [50].
4.13. Cell Viability and Proliferation Assay
Cells were transfected by NucleofectorTM (Amaxa, Gaithersburg, MA, USA) with 2 µg of each
construct and plated (1600 cells/well) on 96-well plates in EndoGRO MV-VEGF medium. 20 h after
transfection, cells were starved in DMEM containing 2% FBS for 4 h. After starvation, EndoGRO
MV-VEGF and DMEM 2% FBS with or without agents to be tested were added (12 wells/condition)
to cutured cells. EndoGRO MV-VEGF was used as positive control, whereas 2% FBS served as
negative control. 24, 48 and 72 h after treatments, cells were washed with PBS and colored using the
CellTiter 96 AQueous Non-Radioactive cell proliferation assay (Promega, Madison, WI, USA). Assays
were performed by adding 40 µL of MTS-containing solution to each culture well and absorbance
was recorded at 495 nm in a microplate reader (Dinnex Technologies MR422, Thermo Labsystems,
Philadelphia, PA, USA) after 2 and 4 h of incubation.
For siRNA-mediated silencing on hTERT PTEC, Oligofection (Oligofectamine, Life Science) of
siRNA duplexes was performed twice (at 0 and 24 h) with 200 pmol siLuc (control, siCNTRL) or
siTRPV2 (see also “Cell cultures and transfection” section). 6 h after the second pulse hTERT PTEC were
plated (2500 cells/well) on 96-well plates in EndoGRO MV-VEGF medium. Proliferation was evaluated
using Cell Proliferation ELISA, BrdU (colorimetric, Roche) following manufacturer instruction. Briefly,
48 h after the first pulse, cells were labelled with BrDU 10 µL/well overnight. ELISA assay was
performed by adding Add 100 µL/ well anti-BrdU-POD working solution for 90 min and subsequently
adding 100 µL/well Substrate solution until color development is sufficient for photometric detection
(5–30 min). Absorbance was measureed the absorbance of the samples in the microplate reader at 370
nm (reference wavelength: approx. 492 nm).
4.14. Scratch-Wound Healing Assay
Cells were transfected by NucleofectorTM with 2 µg of each construct, as previously described,
and plated (10 × 104 cells/well) using EndoGRO MV-VEGF on 24-well culture plates coated with
1% gelatin. 20 h after transfection, cell monolayers were starved for 4 h in DMEM 0% FBS. Motility
assay was performed by generating a wound in the confluent cellular monolayers by means of a
P10-pipette tip. Floating cells were removed by two washes in PBS solution, and monolayers were
treated with test conditions (in duplicate). Complete EndoGRO 5% FBS was used as positive control,
whereas DMEM 0% FBS served as negative control. Experiments were performed using a Nikon
Eclipse Ti (Nikon Corporation, Tokyo, Japan) inverted microscope equipped with a A.S.I. MS-2000
stage and a OkoLab incubator (to keep cells at 37 ◦C and 5% CO2). Images were acquired at 2 h
time intervals for 5 time points, using a Nikon Plan 4×/0.10 objective and a CCD camera. Within two
subsequent time points, MetaMorph software (Molecular Devices) was used to measure the distance
covered by cells to close the “wound area” (four field measurements for each image, at least 10 fields
for each condition analyzed in each independent experiment) and to calculate migration rate (%).
4.15. Random Migration Assay
HMEC were transfected by NucleofectorTM with 2 µg of each construct. Cells were plated
(1.5 × 104 cells/well), using EndoGRO MV-VEGF for HMEC on 24-well culture plates coated with 1%
gelatin. 20 h after transfection, cells were starved for 4 h in DMEM 0%. EndoGRO 5% FBS was used
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as positive control, whereas DMEM 0% FBS was the negative control for HMEC. Experiments were
performed using the same set-up described for the wound healing assays but using a Nikon Plan
10×/0.10 objective. Images were acquired for 10 h every 10 min using MetaMorph software. Image
stacks were analyzed with ImageJ software and at least 500 cells/condition were tracked. Migration
rate (µm/s) is obtained by measuring the distance covered by cells between two subsequent time
points after conversion of pixels to micrometers. Directional migration index, or cell persistence, was
calculated as the Euclidean distance from the initial position of each cell to the final point of its path
(i.e., straight line from initial to final positions) divided by the total path length (sum of the distances
covered between each acquisition). The value obtained was then normalized to the total duration of
the cell tracking and then multiplied by the square root of the cell tracking duration, as previously
described [49].
4.16. Cell Attraction Assay
HMEC (10 × 104 cells/well) and PTEC (5 × 104 cells/well) were plated in 24-well plates
(2 wells/condition) using EndoGRO MV-VEGF medium. After 24 h, Transwell® permeable supports
(6.5 mm inserts with an 8 µm pore polycarbonate membrane) were equilibrated for 20 s at 37 ◦C
using RPMI 0% FBS medium. The equilibrated Transwell® inserts were then placed over the wells
containing the previously plated HMEC and PTEC. PC3 cells (5 × 104 cells/insert) were seeded in the
Transwell® inserts using RPMI 0% FBS and incubated for 24 h. Transwell® inserts were then washed
in PBS twice and fixed in methanol for 30’. PC3 cells were then colored with 0.5% Crystal Violet in
methanol for 20 s at room temperature and after washed in PBS. PC3 cells that did not migrate thought
the membrane pores were removed from the upper side of the membrane using a cotton bud. PC3 cells
that migrated thought the membrane pores were then counted using an Eclipse Ti-E Nikon microscope
with a 10×/0.25 NA Plan objective.
4.17. 2D Chemotaxis Assay
6 µL of PC3 cell suspension (3 × 106 cells/mL) were plated in the observation area (3 observation
areas/chamber) of a µ-Slide Chemotaxis chamber (ibidi GmbH, Gräfelfing, Germany) using RPMI 10%
FBS medium and incubated to allow cell attachment. After 6 h, 65 µL of control medium (EndoGRO
basal medium) were added to the right reservoirs of the chamber (3 right reservoirs/chamber). 65 µL
of control basal medium or PTEC/HMEC/TRPC3-overexpressing HMEC conditioned medium were
added to the left reservoirs of the chamber (3 left reservoirs/chamber). Experiments were performed
using the same set-up described for the wound healing assays with a Nikon Plan 10×/0.10 objective.
Images of the observations chambers were acquired for 10 h every 10 min using MetaMorph software.
Image stacks were analyzed with ImageJ software.
4.18. In Vitro Tubulogenesis
In Vitro formation of capillary-like structures was studied on growth factor-reduced Matrigel
(Corning, Corning, NY, USA) for HMEC and a solution of 40% growth factor-reduced Matrigel and 60%
Collagen-I 4 mg/mL gel obtained by mixing 1 M HEPES, 37 g/L NaHCO3, and 5 mg/mL collagen-I in a
1:1:8 ratio (Cultrex 3D Culture Matrix Rat Collagen I, Amsbio) for PTEC-hTERT. HMEC were transfected
by NucleofectorTM with 2 µg of each construct, as previously described. 24 h after transfection, cells
were seeded (3.5 × 104 cells/ well) onto Matrigel-coated 24-well plates in growth medium containing
treatments (in duplicate). For siRNA-mediated silencing on PTEC-hTERT, Oligofection (Oligofectamine,
Life Science) of siRNA duplexes was performed twice (at 0 and 24 h) with 200 pmol siLuc (control,
siCNTRL) or siTRPA1 (see also “Cell cultures and transfection” section). EndoGRO 5% FBS was used
as positive control and DMEM 10% FBS as negative control. Cell organization onto Matrigel was
periodically observed with the same set-up as the one used for wound healing and migration assays
using a Nikon Plan 10×/0.10 objective. Images were acquired at 2 h time intervals (10 time points) using
MetaMorph software. In order to quantify tubulogenesis images, we used the Angiogenesis Analyzer
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plugin of the ImageJ software, developed by Gilles Carpentier (ImageJ contribution: Angiogenesis
Analyzer. ImageJ News, 5 October 2012). Angiogenesis Analyzer allows the analysis of cellular
networks by the detection of different characteristics and constitutive elements of tubules. In order
to measure differences in cell ability to from pseudo-capillary structures in vitro, we quantified the
number of master junctions and the total master segments length. Master junctions are defined as
portions of tree delimited by two junctions, none exclusively implicated with one branch. The total
master segment length is the sum of the length of the detected master segments in the analyzed area,
where master segments are the elements delimited by two master junctions.
4.19. Statistical Analysis
Statistical analysis was performed using R 3.4.2 software and Kaleidagraph Software (Synergy
Software, Reading PA, USA). Statistical significance between populations was determined by Student’s
t-test (for normal populations) or non-parametric Wilcoxon-Mann-Whithney test. Differences with
p-values < 0.05 were considered statistically significant. Heatmap: A heatmap was generated to represent
and visualize the relative expression pattern of TRP genes. Figure 1a was produced with Complex
Heatmap package 1.14.0. (https://bioconductor.org/packages/release/bioc/html/ComplexHeatmap.html).
Euclidean distance and Ward’s aggregation criterion were used to perform the hierarchical classification
of the channels. The color key displayed in heatmap was prepared by putting the color breaks to
log2 fold change values as follows: red, −4 to −2; black, −2 to +2 and green, 2 to 4. Normalization of
relative expressions patterns: all experiments, except the ones involving TRPP2, were carried with at
least two technical and three biological replicates for each experimental condition. For TRPP2, only two
biological replicates were used. All initial values (∆∆CT) were log2 transformed in order to stabilize the
variance and directly observe the log2 fold changes (log2FC). Values of technical replicates were averaged
before the log2 transformations. Relative expression pattern was obtained by subtraction of the healthy
counterpart to the log2-averages of each biological sample. Differential analysis: Differential analysis of
∆∆CT between PTEC1-3 samples and HPrMEC samples was performed with non-parametric Wilcoxon
tests for unpaired data, without averaging technical replicates. In order to take into account the multiple
testing issue, raw p-values were adjusted using the Benjamini-Hochberg method [51], which controls
the false discovery rate (FDR). Differences with adjusted p-values < 0.05 were considered statistically
significant except for Figure 1b for which significance was at 0.1 (Figure 1b).
5. Conclusions
We performed a complete expression profiling and functional screening that clearly identified
four ‘prostate-associated’ genes that are deregulated during PCa vascularization, three of which have
profound effects on EC biology. In particular, three out of the selected ‘prostate-associated’ channels are
overexpressed in PCa ECs and have marked effects on the main EC properties including proliferation
(TRPV2), TEC-mediated crosstalk with cancer cells (TRPC3) and angiogenesis (TRPA1). The expression
profile and functional data could indeed explain the specific transition of PCa to its aggressive
phenotype. PTEC have been previously shown to exhibit aggressive phenotypes typical of TECs:
indeed, PTEC have a higher migration rate than normal HMECs and are able to form capillary-like
structures both in vitro and in xenografts in SCID mice [18]. These results could be of great importance
to explain, at least part, the aggressive phenotype previously observed in PTEC relative to that in
normal HUVEC and HMEC [18] and provide new putative therapeutic targets.
6. Patents
The authors disclose the Report of Invention: “Set de oliginucleotides de qPCR pour l’établissement
de profil d’expression du domaine fonctionnel des 26 canaux de type TRP” Reference # DSO2018005437),
Patent Pending (D.G., M.B., N.P.) and thus the exact primer sequences and positions under declaration
of invention cannot be stated.
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